Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal Logo BIA

Home page

CIMMAP ANR coordinated by Marie Bodinier

ANR CIMMAP
The aim of this project is to characterize the effects of an antenatal prebiotics supplementation on the immune system maturation and the composition of the intestinal microbiota and milk in order to prevent infant allergy.

Allergies affect 30-40% of the world's population. Among them, atopic dermatitis is one of the most recurrent and early. Allergies are influenced by genetic (including early functional alteration of the skin barrier) and environmental factors. There are associated with a dysregulated immune system and a decreased gut microbiota diversity.

CIMMAP (Characterising the effect of maternal prebiotic supplementation on perinatal Immune system maturation, Gut Microbiota and breast Milk compositions for Allergy Prevention in high-risk children) will explore the perinatal period among children at risk for allergy by focusing on:

  • immune system development and gut microbiota maturation
  • the composition of breast milk and its influence on those factors
  • the modulation of the infant immune system by maternal gut microbiota and its derived products
  • the effect of prebiotics on gut microbiota, breast milk and immune system

This project should improve our understanding of the occurrence of allergic pathologies and, from an industrial perspective, yield new opportunities to develop foods enriched in prebiotics to prevent allergies.
CIMMAP is an ancillary study based on the PREGRALL clinical study funded by the French Ministry of Health, which will be launched in November 2017 and aims to evaluate for the first time a maternal antenatal prebiotic (GOS / Inulin) supplementation on atopic dermatitis occurrence in children of high allergic risk.

  

See also

This project involves a consortium of 7 partners:

CIMMAP brings together science-based academics (immunologists, microbiologists, physiologists, omics specialists, molecular biologists and statisticians) as well as clinical dermatologists, paediatric dermatologists and obstetricians.